http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 16 Jul 2026 12:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Illumina+expands+Billion+Cell+Atlas+program+with+new+AI+drug+developers/26778479.html <div class="xn-content"> <p class="prntac"><i>Partners will use unprecedented data scale to advance more precise medicines to approval</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ILMN" idsrc="xmltag.org" >Illumina, Inc.</span> (NASDAQ: ILMN) today announced that the Billion Cell Atlas alliance has added three new member companies, including AI-native drug developer <span value="ACORN:5021692942" idsrc="xmltag.org" >Formation Bio</span>. As leaders in AI-driven drug discovery, design, and development, alliance members will use the unprecedented scale of Illumina's genome-wide perturbation data as infrastructure for the next generation of therapeutics.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Illumina+expands+Billion+Cell+Atlas+program+with+new+AI+drug+developers/26778479.html Thu, 16 Jul 2026 12:00:00 -0400 A.50216929 ILMN O.00024621 O.57132712 http://www.streetinsider.com/Press+Releases/Illumina+expands+Billion+Cell+Atlas+program+with+new+AI+drug+developers/26778479.html <div class="xn-content"> <p class="prntac"><i>Partners will use unprecedented data scale to advance more precise medicines to approval</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ILMN" idsrc="xmltag.org" >Illumina, Inc.</span> (NASDAQ: ILMN) today announced that the Billion Cell Atlas alliance has added three new member companies, including AI-native drug developer <span value="ACORN:5021692942" idsrc="xmltag.org" >Formation Bio</span>. As leaders in AI-driven drug discovery, design, and development, alliance members will use the unprecedented scale of Illumina's genome-wide perturbation data as infrastructure for the next generation of therapeutics.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Illumina+expands+Billion+Cell+Atlas+program+with+new+AI+drug+developers/26778479.html Thu, 16 Jul 2026 12:00:00 -0400 A.50216929 ILMN O.00024621 O.57132712 http://www.streetinsider.com/Press+Releases/Illumina+expands+Billion+Cell+Atlas+program+with+new+AI+drug+developers/26778479.html <div class="xn-content"> <p class="prntac"><i>Partners will use unprecedented data scale to advance more precise medicines to approval</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ILMN" idsrc="xmltag.org" >Illumina, Inc.</span> (NASDAQ: ILMN) today announced that the Billion Cell Atlas alliance has added three new member companies, including AI-native drug developer <span value="ACORN:5021692942" idsrc="xmltag.org" >Formation Bio</span>. As leaders in AI-driven drug discovery, design, and development, alliance members will use the unprecedented scale of Illumina's genome-wide perturbation data as infrastructure for the next generation of therapeutics.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Illumina+expands+Billion+Cell+Atlas+program+with+new+AI+drug+developers/26778479.html Thu, 16 Jul 2026 12:00:00 -0400 A.50216929 ILMN O.00024621 O.57132712 http://www.streetinsider.com/Press+Releases/Illumina+expands+Billion+Cell+Atlas+program+with+new+AI+drug+developers/26778479.html <div class="xn-content"> <p class="prntac"><i>Partners will use unprecedented data scale to advance more precise medicines to approval</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ILMN" idsrc="xmltag.org" >Illumina, Inc.</span> (NASDAQ: ILMN) today announced that the Billion Cell Atlas alliance has added three new member companies, including AI-native drug developer <span value="ACORN:5021692942" idsrc="xmltag.org" >Formation Bio</span>. As leaders in AI-driven drug discovery, design, and development, alliance members will use the unprecedented scale of Illumina's genome-wide perturbation data as infrastructure for the next generation of therapeutics.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Illumina+expands+Billion+Cell+Atlas+program+with+new+AI+drug+developers/26778479.html Thu, 16 Jul 2026 12:00:00 -0400 A.50216929 ILMN O.00024621 O.57132712 http://www.streetinsider.com/PRNewswire/Illumina+expands+Billion+Cell+Atlas+program+with+new+AI+drug+developers/26778479.html <div class="xn-content"> <p class="prntac"><i>Partners will use unprecedented data scale to advance more precise medicines to approval</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ILMN" idsrc="xmltag.org" >Illumina, Inc.</span> (NASDAQ: ILMN) today announced that the Billion Cell Atlas alliance has added three new member companies, including AI-native drug developer <span value="ACORN:5021692942" idsrc="xmltag.org" >Formation Bio</span>. As leaders in AI-driven drug discovery, design, and development, alliance members will use the unprecedented scale of Illumina's genome-wide perturbation data as infrastructure for the next generation of therapeutics.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Illumina+expands+Billion+Cell+Atlas+program+with+new+AI+drug+developers/26778479.html Thu, 16 Jul 2026 12:00:00 -0400 A.50216929 ILMN O.00024621 O.57132712 http://www.streetinsider.com/PRNewswire/Illumina+expands+Billion+Cell+Atlas+program+with+new+AI+drug+developers/26778479.html <div class="xn-content"> <p class="prntac"><i>Partners will use unprecedented data scale to advance more precise medicines to approval</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ILMN" idsrc="xmltag.org" >Illumina, Inc.</span> (NASDAQ: ILMN) today announced that the Billion Cell Atlas alliance has added three new member companies, including AI-native drug developer <span value="ACORN:5021692942" idsrc="xmltag.org" >Formation Bio</span>. As leaders in AI-driven drug discovery, design, and development, alliance members will use the unprecedented scale of Illumina's genome-wide perturbation data as infrastructure for the next generation of therapeutics.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Illumina+expands+Billion+Cell+Atlas+program+with+new+AI+drug+developers/26778479.html Thu, 16 Jul 2026 12:00:00 -0400 A.50216929 ILMN O.00024621 O.57132712 http://www.streetinsider.com/PRNewswire/Illumina+expands+Billion+Cell+Atlas+program+with+new+AI+drug+developers/26778479.html <div class="xn-content"> <p class="prntac"><i>Partners will use unprecedented data scale to advance more precise medicines to approval</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ILMN" idsrc="xmltag.org" >Illumina, Inc.</span> (NASDAQ: ILMN) today announced that the Billion Cell Atlas alliance has added three new member companies, including AI-native drug developer <span value="ACORN:5021692942" idsrc="xmltag.org" >Formation Bio</span>. As leaders in AI-driven drug discovery, design, and development, alliance members will use the unprecedented scale of Illumina's genome-wide perturbation data as infrastructure for the next generation of therapeutics.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Illumina+expands+Billion+Cell+Atlas+program+with+new+AI+drug+developers/26778479.html Thu, 16 Jul 2026 12:00:00 -0400 A.50216929 ILMN O.00024621 O.57132712 http://www.streetinsider.com/PRNewswire/Illumina+expands+Billion+Cell+Atlas+program+with+new+AI+drug+developers/26778479.html <div class="xn-content"> <p class="prntac"><i>Partners will use unprecedented data scale to advance more precise medicines to approval</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ILMN" idsrc="xmltag.org" >Illumina, Inc.</span> (NASDAQ: ILMN) today announced that the Billion Cell Atlas alliance has added three new member companies, including AI-native drug developer <span value="ACORN:5021692942" idsrc="xmltag.org" >Formation Bio</span>. As leaders in AI-driven drug discovery, design, and development, alliance members will use the unprecedented scale of Illumina's genome-wide perturbation data as infrastructure for the next generation of therapeutics.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Illumina+expands+Billion+Cell+Atlas+program+with+new+AI+drug+developers/26778479.html Thu, 16 Jul 2026 12:00:00 -0400 A.50216929 ILMN O.00024621 O.57132712 http://www.streetinsider.com/Analyst+PT+Change/Illumina+%28ILMN%29+PT+Raised+to+%24190+at+Canaccord/26764498.html Canaccord analyst Kyle Mikson raised the price target on Illumina (NASDAQ: ILMN) to $190.00 (from $140.00) while maintaining a Hold rating. http://www.streetinsider.com/Analyst+PT+Change/Illumina+%28ILMN%29+PT+Raised+to+%24190+at+Canaccord/26764498.html Tue, 14 Jul 2026 06:42:22 -0400 ILMN http://www.streetinsider.com/Analyst+PT+Change/Illumina+%28ILMN%29+PT+Raised+to+%24208+at+Baird/26759708.html Baird analyst Catherine Ramsey Schulte raised the price target on Illumina (NASDAQ: ILMN) to $208.00 (from $137.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/Illumina+%28ILMN%29+PT+Raised+to+%24208+at+Baird/26759708.html Mon, 13 Jul 2026 07:18:28 -0400 ILMN http://www.streetinsider.com/Press+Releases/Illumina+to+Announce+Second+Quarter+2026+Financial+Results+on+Thursday%2C+July+30%2C+2026/26753209.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ILMN" idsrc="xmltag.org" >Illumina, Inc.</span> (NASDAQ: ILMN) announced today that it will issue results for the second quarter 2026 following the close of market on <chron>Thursday, July 30, 2026</chron>.</p> <p>On the same day, at <chron>1:30 pm Pacific Time</chron> (<chron>4:30 pm Eastern Time</chron>) <person>Jacob Thaysen</person>, PhD, Chief Executive Officer, and <person>Ankur Dhingra</person>, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. </p><p><b>Conference Call Details</b></p><p>The conference call will begin at <chron>1:30 pm Pacific Time</chron> (<chron>4:30 pm Eastern Time</chron>) on http://www.streetinsider.com/Press+Releases/Illumina+to+Announce+Second+Quarter+2026+Financial+Results+on+Thursday%2C+July+30%2C+2026/26753209.html Thu, 09 Jul 2026 16:05:00 -0400 ILMN O.00024621 http://www.streetinsider.com/Press+Releases/Illumina+to+Announce+Second+Quarter+2026+Financial+Results+on+Thursday%2C+July+30%2C+2026/26753209.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ILMN" idsrc="xmltag.org" >Illumina, Inc.</span> (NASDAQ: ILMN) announced today that it will issue results for the second quarter 2026 following the close of market on <chron>Thursday, July 30, 2026</chron>.</p> <p>On the same day, at <chron>1:30 pm Pacific Time</chron> (<chron>4:30 pm Eastern Time</chron>) <person>Jacob Thaysen</person>, PhD, Chief Executive Officer, and <person>Ankur Dhingra</person>, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. </p><p><b>Conference Call Details</b></p><p>The conference call will begin at <chron>1:30 pm Pacific Time</chron> (<chron>4:30 pm Eastern Time</chron>) on http://www.streetinsider.com/Press+Releases/Illumina+to+Announce+Second+Quarter+2026+Financial+Results+on+Thursday%2C+July+30%2C+2026/26753209.html Thu, 09 Jul 2026 16:05:00 -0400 ILMN O.00024621 http://www.streetinsider.com/PRNewswire/Illumina+to+Announce+Second+Quarter+2026+Financial+Results+on+Thursday%2C+July+30%2C+2026/26753209.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ILMN" idsrc="xmltag.org" >Illumina, Inc.</span> (NASDAQ: ILMN) announced today that it will issue results for the second quarter 2026 following the close of market on <chron>Thursday, July 30, 2026</chron>.</p> <p>On the same day, at <chron>1:30 pm Pacific Time</chron> (<chron>4:30 pm Eastern Time</chron>) <person>Jacob Thaysen</person>, PhD, Chief Executive Officer, and <person>Ankur Dhingra</person>, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. </p><p><b>Conference Call Details</b></p><p>The conference call will begin at <chron>1:30 pm Pacific Time</chron> (<chron>4:30 pm Eastern Time</chron>) on http://www.streetinsider.com/PRNewswire/Illumina+to+Announce+Second+Quarter+2026+Financial+Results+on+Thursday%2C+July+30%2C+2026/26753209.html Thu, 09 Jul 2026 16:05:00 -0400 ILMN O.00024621 http://www.streetinsider.com/PRNewswire/Illumina+to+Announce+Second+Quarter+2026+Financial+Results+on+Thursday%2C+July+30%2C+2026/26753209.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ILMN" idsrc="xmltag.org" >Illumina, Inc.</span> (NASDAQ: ILMN) announced today that it will issue results for the second quarter 2026 following the close of market on <chron>Thursday, July 30, 2026</chron>.</p> <p>On the same day, at <chron>1:30 pm Pacific Time</chron> (<chron>4:30 pm Eastern Time</chron>) <person>Jacob Thaysen</person>, PhD, Chief Executive Officer, and <person>Ankur Dhingra</person>, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. </p><p><b>Conference Call Details</b></p><p>The conference call will begin at <chron>1:30 pm Pacific Time</chron> (<chron>4:30 pm Eastern Time</chron>) on http://www.streetinsider.com/PRNewswire/Illumina+to+Announce+Second+Quarter+2026+Financial+Results+on+Thursday%2C+July+30%2C+2026/26753209.html Thu, 09 Jul 2026 16:05:00 -0400 ILMN O.00024621 http://www.streetinsider.com/Management+Changes/Illumina+names+new+chief+commercial+and+chief+legal+officers/26751109.html <p>Illumina, Inc. (NASDAQ: ILMN) has appointed Mike Sullivan as Chief Commercial Officer and Julie Coletti as Chief Legal Officer, according to a company statement. Sullivan's appointment takes effect July 20, 2026, and Coletti's on August 3, 2026.</p> <p>Sullivan will lead Illumina's global commercial organization. He has more than 30 years of commercial leadership experience in diagnostics, precision medicine, healthcare, and life sciences. He most recently served as Chief Commercial Officer at Caris Life Sciences, overseeing global commercial operations across oncology diagnostics and precision medicine. Prior to that, he held senior roles at Roche Diagnostics, Ortho Clinical Diagnostics, IDEXX Laboratories, and Abbott http://www.streetinsider.com/Management+Changes/Illumina+names+new+chief+commercial+and+chief+legal+officers/26751109.html Thu, 09 Jul 2026 09:05:16 -0400 A.02843176 A.08801724 A.19730566 A.50201100 ILMN O.00024621 O.00264650 O.00268852 O.01214773 O.02747122 http://www.streetinsider.com/Management+Changes/Illumina+names+new+chief+commercial+and+chief+legal+officers/26751109.html <p>Illumina, Inc. (NASDAQ: ILMN) has appointed Mike Sullivan as Chief Commercial Officer and Julie Coletti as Chief Legal Officer, according to a company statement. Sullivan's appointment takes effect July 20, 2026, and Coletti's on August 3, 2026.</p> <p>Sullivan will lead Illumina's global commercial organization. He has more than 30 years of commercial leadership experience in diagnostics, precision medicine, healthcare, and life sciences. He most recently served as Chief Commercial Officer at Caris Life Sciences, overseeing global commercial operations across oncology diagnostics and precision medicine. Prior to that, he held senior roles at Roche Diagnostics, Ortho Clinical Diagnostics, IDEXX Laboratories, and Abbott http://www.streetinsider.com/Management+Changes/Illumina+names+new+chief+commercial+and+chief+legal+officers/26751109.html Thu, 09 Jul 2026 09:05:16 -0400 A.02843176 A.08801724 A.19730566 A.50201100 ILMN O.00024621 O.00264650 O.00268852 O.01214773 O.02747122 http://www.streetinsider.com/Management+Changes/Illumina+names+new+chief+commercial+and+chief+legal+officers/26751109.html <p>Illumina, Inc. (NASDAQ: ILMN) has appointed Mike Sullivan as Chief Commercial Officer and Julie Coletti as Chief Legal Officer, according to a company statement. Sullivan's appointment takes effect July 20, 2026, and Coletti's on August 3, 2026.</p> <p>Sullivan will lead Illumina's global commercial organization. He has more than 30 years of commercial leadership experience in diagnostics, precision medicine, healthcare, and life sciences. He most recently served as Chief Commercial Officer at Caris Life Sciences, overseeing global commercial operations across oncology diagnostics and precision medicine. Prior to that, he held senior roles at Roche Diagnostics, Ortho Clinical Diagnostics, IDEXX Laboratories, and Abbott http://www.streetinsider.com/Management+Changes/Illumina+names+new+chief+commercial+and+chief+legal+officers/26751109.html Thu, 09 Jul 2026 09:05:16 -0400 A.02843176 A.08801724 A.19730566 A.50201100 ILMN O.00024621 O.00264650 O.00268852 O.01214773 O.02747122 http://www.streetinsider.com/Management+Changes/Illumina+names+new+chief+commercial+and+chief+legal+officers/26751109.html <p>Illumina, Inc. (NASDAQ: ILMN) has appointed Mike Sullivan as Chief Commercial Officer and Julie Coletti as Chief Legal Officer, according to a company statement. Sullivan's appointment takes effect July 20, 2026, and Coletti's on August 3, 2026.</p> <p>Sullivan will lead Illumina's global commercial organization. He has more than 30 years of commercial leadership experience in diagnostics, precision medicine, healthcare, and life sciences. He most recently served as Chief Commercial Officer at Caris Life Sciences, overseeing global commercial operations across oncology diagnostics and precision medicine. Prior to that, he held senior roles at Roche Diagnostics, Ortho Clinical Diagnostics, IDEXX Laboratories, and Abbott http://www.streetinsider.com/Management+Changes/Illumina+names+new+chief+commercial+and+chief+legal+officers/26751109.html Thu, 09 Jul 2026 09:05:16 -0400 A.02843176 A.08801724 A.19730566 A.50201100 ILMN O.00024621 O.00264650 O.00268852 O.01214773 O.02747122 http://www.streetinsider.com/Management+Changes/Illumina+names+new+chief+commercial+and+chief+legal+officers/26751109.html <p>Illumina, Inc. (NASDAQ: ILMN) has appointed Mike Sullivan as Chief Commercial Officer and Julie Coletti as Chief Legal Officer, according to a company statement. Sullivan's appointment takes effect July 20, 2026, and Coletti's on August 3, 2026.</p> <p>Sullivan will lead Illumina's global commercial organization. He has more than 30 years of commercial leadership experience in diagnostics, precision medicine, healthcare, and life sciences. He most recently served as Chief Commercial Officer at Caris Life Sciences, overseeing global commercial operations across oncology diagnostics and precision medicine. Prior to that, he held senior roles at Roche Diagnostics, Ortho Clinical Diagnostics, IDEXX Laboratories, and Abbott http://www.streetinsider.com/Management+Changes/Illumina+names+new+chief+commercial+and+chief+legal+officers/26751109.html Thu, 09 Jul 2026 09:05:16 -0400 A.02843176 A.08801724 A.19730566 A.50201100 ILMN O.00024621 O.00264650 O.00268852 O.01214773 O.02747122 http://www.streetinsider.com/Management+Changes/Illumina+names+new+chief+commercial+and+chief+legal+officers/26751109.html <p>Illumina, Inc. (NASDAQ: ILMN) has appointed Mike Sullivan as Chief Commercial Officer and Julie Coletti as Chief Legal Officer, according to a company statement. Sullivan's appointment takes effect July 20, 2026, and Coletti's on August 3, 2026.</p> <p>Sullivan will lead Illumina's global commercial organization. He has more than 30 years of commercial leadership experience in diagnostics, precision medicine, healthcare, and life sciences. He most recently served as Chief Commercial Officer at Caris Life Sciences, overseeing global commercial operations across oncology diagnostics and precision medicine. Prior to that, he held senior roles at Roche Diagnostics, Ortho Clinical Diagnostics, IDEXX Laboratories, and Abbott http://www.streetinsider.com/Management+Changes/Illumina+names+new+chief+commercial+and+chief+legal+officers/26751109.html Thu, 09 Jul 2026 09:05:16 -0400 A.02843176 A.08801724 A.19730566 A.50201100 ILMN O.00024621 O.00264650 O.00268852 O.01214773 O.02747122 http://www.streetinsider.com/Management+Changes/Illumina+names+new+chief+commercial+and+chief+legal+officers/26751109.html <p>Illumina, Inc. (NASDAQ: ILMN) has appointed Mike Sullivan as Chief Commercial Officer and Julie Coletti as Chief Legal Officer, according to a company statement. Sullivan's appointment takes effect July 20, 2026, and Coletti's on August 3, 2026.</p> <p>Sullivan will lead Illumina's global commercial organization. He has more than 30 years of commercial leadership experience in diagnostics, precision medicine, healthcare, and life sciences. He most recently served as Chief Commercial Officer at Caris Life Sciences, overseeing global commercial operations across oncology diagnostics and precision medicine. Prior to that, he held senior roles at Roche Diagnostics, Ortho Clinical Diagnostics, IDEXX Laboratories, and Abbott http://www.streetinsider.com/Management+Changes/Illumina+names+new+chief+commercial+and+chief+legal+officers/26751109.html Thu, 09 Jul 2026 09:05:16 -0400 A.02843176 A.08801724 A.19730566 A.50201100 ILMN O.00024621 O.00264650 O.00268852 O.01214773 O.02747122 http://www.streetinsider.com/Management+Changes/Illumina+names+new+chief+commercial+and+chief+legal+officers/26751109.html <p>Illumina, Inc. (NASDAQ: ILMN) has appointed Mike Sullivan as Chief Commercial Officer and Julie Coletti as Chief Legal Officer, according to a company statement. Sullivan's appointment takes effect July 20, 2026, and Coletti's on August 3, 2026.</p> <p>Sullivan will lead Illumina's global commercial organization. He has more than 30 years of commercial leadership experience in diagnostics, precision medicine, healthcare, and life sciences. He most recently served as Chief Commercial Officer at Caris Life Sciences, overseeing global commercial operations across oncology diagnostics and precision medicine. Prior to that, he held senior roles at Roche Diagnostics, Ortho Clinical Diagnostics, IDEXX Laboratories, and Abbott http://www.streetinsider.com/Management+Changes/Illumina+names+new+chief+commercial+and+chief+legal+officers/26751109.html Thu, 09 Jul 2026 09:05:16 -0400 A.02843176 A.08801724 A.19730566 A.50201100 ILMN O.00024621 O.00264650 O.00268852 O.01214773 O.02747122 http://www.streetinsider.com/Management+Changes/Illumina+names+new+chief+commercial+and+chief+legal+officers/26751109.html <p>Illumina, Inc. (NASDAQ: ILMN) has appointed Mike Sullivan as Chief Commercial Officer and Julie Coletti as Chief Legal Officer, according to a company statement. Sullivan's appointment takes effect July 20, 2026, and Coletti's on August 3, 2026.</p> <p>Sullivan will lead Illumina's global commercial organization. He has more than 30 years of commercial leadership experience in diagnostics, precision medicine, healthcare, and life sciences. He most recently served as Chief Commercial Officer at Caris Life Sciences, overseeing global commercial operations across oncology diagnostics and precision medicine. Prior to that, he held senior roles at Roche Diagnostics, Ortho Clinical Diagnostics, IDEXX Laboratories, and Abbott http://www.streetinsider.com/Management+Changes/Illumina+names+new+chief+commercial+and+chief+legal+officers/26751109.html Thu, 09 Jul 2026 09:05:16 -0400 A.02843176 A.08801724 A.19730566 A.50201100 ILMN O.00024621 O.00264650 O.00268852 O.01214773 O.02747122 http://www.streetinsider.com/Management+Changes/Illumina+names+new+chief+commercial+and+chief+legal+officers/26751109.html <p>Illumina, Inc. (NASDAQ: ILMN) has appointed Mike Sullivan as Chief Commercial Officer and Julie Coletti as Chief Legal Officer, according to a company statement. Sullivan's appointment takes effect July 20, 2026, and Coletti's on August 3, 2026.</p> <p>Sullivan will lead Illumina's global commercial organization. He has more than 30 years of commercial leadership experience in diagnostics, precision medicine, healthcare, and life sciences. He most recently served as Chief Commercial Officer at Caris Life Sciences, overseeing global commercial operations across oncology diagnostics and precision medicine. Prior to that, he held senior roles at Roche Diagnostics, Ortho Clinical Diagnostics, IDEXX Laboratories, and Abbott http://www.streetinsider.com/Management+Changes/Illumina+names+new+chief+commercial+and+chief+legal+officers/26751109.html Thu, 09 Jul 2026 09:05:16 -0400 A.02843176 A.08801724 A.19730566 A.50201100 ILMN O.00024621 O.00264650 O.00268852 O.01214773 O.02747122 http://www.streetinsider.com/Press+Releases/Illumina+appoints+Michael+Sullivan+Chief+Commercial+Officer+and+Julie+Coletti+Chief+Legal+Officer/26751105.html <div class="xn-content"> <p class="prntac"><i>New leaders bring extensive leadership experience across life sciences, diagnostics, and medical technology</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ILMN" idsrc="xmltag.org" >Illumina, Inc.</span> (NASDAQ: ILMN) today announced the appointment of <person>Mike Sullivan</person> as Chief Commercial Officer, effective <chron>July 20, 2026</chron>, and <person>Julie Coletti</person> as Chief Legal Officer, effective <chron>August 3, 2026</chron>.</p> <p>The appointments add experienced leaders to Illumina's Executive Leadership Team as the company continues advancing its strategy, serving customers, driving growth, and delivering on its mission to improve human health around the world.</p><p>"We are excited to welcome Mike and Julie to Illumina," http://www.streetinsider.com/Press+Releases/Illumina+appoints+Michael+Sullivan+Chief+Commercial+Officer+and+Julie+Coletti+Chief+Legal+Officer/26751105.html Thu, 09 Jul 2026 09:05:00 -0400 A.02843176 A.08801724 A.19730566 A.50201100 ILMN O.00024621 O.00264650 O.00268852 O.01214773 O.02747122